Wegovy is the first drug in India approved for both weight management and risk reduction of major adverse cardiovascular events in individuals with established heart disease.

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, though it is exploring oral semaglutide for obesity.

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.